Sk Biopharmaceuticals Co Ltd (326030) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sk Biopharmaceuticals Co Ltd (326030) has a cash flow conversion efficiency ratio of 0.105x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩87.00 Billion ≈ $58.96 Million USD) by net assets (₩826.27 Billion ≈ $559.95 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 326030 equity to assets ratio to measure how much of total assets are equity-financed.
Sk Biopharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Sk Biopharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 326030 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Sk Biopharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sk Biopharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PLDT Inc ADR
NYSE:PHI
|
0.180x |
|
InnoDisk
TWO:5289
|
-0.172x |
|
CENTESSA PHARMACEUTICALS
F:260
|
N/A |
|
ALMONTY INDUSTRIES CDIS/1
F:ALI0
|
-0.035x |
|
AAC TECHNOLOG.HLDG.ADR/
F:A2X
|
N/A |
|
Beijing New Building Materials Public Ltd Co
SHE:000786
|
0.092x |
|
CSW Industrials, Inc.
NYSE:CSW
|
0.027x |
|
Kulicke and Soffa Industries Inc
F:KU1
|
-0.011x |
Annual Cash Flow Conversion Efficiency for Sk Biopharmaceuticals Co Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Sk Biopharmaceuticals Co Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Sk Biopharmaceuticals Co Ltd (326030) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩826.27 Billion ≈ $559.95 Million |
₩176.33 Billion ≈ $119.50 Million |
0.213x | +29.08% |
| 2024-12-31 | ₩573.98 Billion ≈ $388.98 Million |
₩94.90 Billion ≈ $64.31 Million |
0.165x | +156.33% |
| 2023-12-31 | ₩320.95 Billion ≈ $217.50 Million |
₩-94.20 Billion ≈ $-63.84 Million |
-0.294x | +41.90% |
| 2022-12-31 | ₩316.56 Billion ≈ $214.53 Million |
₩-159.92 Billion ≈ $-108.38 Million |
-0.505x | -141.62% |
| 2021-12-31 | ₩444.19 Billion ≈ $301.02 Million |
₩-92.87 Billion ≈ $-62.94 Million |
-0.209x | +62.39% |
| 2020-12-31 | ₩379.07 Billion ≈ $256.89 Million |
₩-210.73 Billion ≈ $-142.81 Million |
-0.556x | -108.90% |
| 2019-12-31 | ₩-13.03 Billion ≈ $-8.83 Million |
₩-81.33 Billion ≈ $-55.12 Million |
6.244x | +359.13% |
| 2018-12-31 | ₩58.63 Billion ≈ $39.73 Million |
₩-141.28 Billion ≈ $-95.74 Million |
-2.410x | -15.76% |
| 2017-12-31 | ₩47.24 Billion ≈ $32.02 Million |
₩-98.34 Billion ≈ $-66.65 Million |
-2.082x | -528.17% |
| 2016-12-31 | ₩147.69 Billion ≈ $100.09 Million |
₩-48.94 Billion ≈ $-33.17 Million |
-0.331x | -- |
About Sk Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, wh… Read more